GlassScriptPhysician profile
Rodrigo Camacho
NPI 1053466276
$4,471.06
in general payments reported to CMS, 2019-2025
27 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what 91% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $156 · 2022: $121 · 2023: $1,245 · 2024: $1,533 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,194.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,194.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,015.87 | 2023-2025 | |
| Regeneron Healthcare Solutions, INC. | $686.86 | 2023-2025 | Dupixent |
| Janssen Biotech, INC. | $295.82 | 2023-2025 | Stelara, Tremfya, Simponi Aria |
| Phathom Pharmaceuticals, INC. | $291.87 | 2024-2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $239.62 | 2021-2022 | |
| Ipsen Biopharmaceuticals, INC | $202.12 | 2025 | Iqirvo |
| Gilead Sciences, INC. | $197.40 | 2025 | Epclusa |
| Aimmune Therapeutics, INC. | $192.94 | 2024-2025 | Zenpep |
| Genzyme Corporation | $177.88 | 2023-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $163.02 | 2023-2025 | Xifaxan, Plenvu |
| Lilly USA, LLC | $159.72 | 2024-2025 | Omvoh |
| Braintree Laboratories, INC. | $140.08 | 2023-2025 | Sutab, Suflave |
| Pfizer INC. | $102.79 | 2023-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $98.70 | 2023-2025 | Entyvio |
| Merck Sharp & Dohme LLC | $75.00 | 2023 | Dificid |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $75.00 | 2023-2025 | Ibsrela |
| Ferring Pharmaceuticals INC. | $72.24 | 2023 | Rebyota |
| Janssen Scientific Affairs, LLC | $62.74 | 2025 | Stelara, Tremfya |
| Tela Bio, INC. | $50.83 | 2025 | Ovitex Reinforced Bioscaffold With Permanent Polymer (Ovitex) |
| Nestle Healthcare Nutrition INC. | $38.83 | 2023 | |
| Novo Nordisk INC | $30.54 | 2021-2025 | Wegovy |
| Madrigal Pharmaceuticals | $30.46 | 2025 | Rezdiffra |
| Exact Sciences Corporation | $18.72 | 2023 | Cologuard Collection Kit |
| Celgene Corporation | $14.88 | 2023 | Zeposia |
| Grifols USA, LLC | $14.20 | 2021 | |
| Shield Therapeutics INC | $13.79 | 2024 | |
| Genentech USA, INC. | $9.14 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rodrigo Camacho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.